Betty Smoot1, Benjamin S Boyd2, Nancy Byl3, Marylin Dodd4. 1. Department of Physical Therapy and Rehabilitation Science, University of California, San Francisco, Box 0736, San Francisco, CA 94143-0736, USA. Electronic address: betty.smoot@ucsf.edu. 2. Department of Physical Therapy, Samuel Merritt University, 450 30th Street, Oakland, CA 94609, USA. 3. Department of Physical Therapy and Rehabilitation Science, University of California, San Francisco, Box 0736, San Francisco, CA 94143-0736, USA. 4. Department of Physiological Nursing, University of California, San Francisco, San Francisco, CA, USA.
Abstract
STUDY DESIGN: Descriptive, cross-sectional. INTRODUCTION: Breast cancer (BC) treatments place the nervous system at risk, which may contribute to upper extremity (UE) mechanosensitivity. PURPOSE OF THE STUDY: To evaluate elbow extension range of motion (EE-ROM) during upper limb neurodynamic testing (ULNT) post-BC treatment. METHODS: ULNT EE-ROM was measured for 145 women post-BC treatment. Women were sub-grouped by presence/absence of pain and lymphedema. RESULTS: Mean EE-ROM during ULNT1 was -22.3° (SD 11.9°) on the unaffected limb and -25.99° (SD 13.1°) on the affected limb. The women with pain and lymphedema had the greatest limitation in EE-ROM during ULNT1 testing, particularly of their affected limb (-33.8°, SD 12.9). Symptoms were reported more frequently in the affected chest, shoulder, arm, elbow, and hand. The intensity of symptoms was greater at the affected chest (p = 0.046), shoulder (p = 0.033) and arm (p = 0.039). CONCLUSIONS: Women with lymphedema and pain after BC treatment may present with altered neural mechanosensitivity. LEVEL OF EVIDENCE: 3a.
STUDY DESIGN: Descriptive, cross-sectional. INTRODUCTION:Breast cancer (BC) treatments place the nervous system at risk, which may contribute to upper extremity (UE) mechanosensitivity. PURPOSE OF THE STUDY: To evaluate elbow extension range of motion (EE-ROM) during upper limb neurodynamic testing (ULNT) post-BC treatment. METHODS: ULNT EE-ROM was measured for 145 womenpost-BC treatment. Women were sub-grouped by presence/absence of pain and lymphedema. RESULTS: Mean EE-ROM during ULNT1 was -22.3° (SD 11.9°) on the unaffected limb and -25.99° (SD 13.1°) on the affected limb. The women with pain and lymphedema had the greatest limitation in EE-ROM during ULNT1 testing, particularly of their affected limb (-33.8°, SD 12.9). Symptoms were reported more frequently in the affected chest, shoulder, arm, elbow, and hand. The intensity of symptoms was greater at the affected chest (p = 0.046), shoulder (p = 0.033) and arm (p = 0.039). CONCLUSIONS:Women with lymphedema and pain after BC treatment may present with altered neural mechanosensitivity. LEVEL OF EVIDENCE: 3a.
Authors: Sarah A McLaughlin; Mary J Wright; Katherine T Morris; Gladys L Giron; Michelle R Sampson; Julia P Brockway; Karen E Hurley; Elyn R Riedel; Kimberly J Van Zee Journal: J Clin Oncol Date: 2008-10-06 Impact factor: 44.544
Authors: Irene de la Rosa Díaz; María Torres Lacomba; Ester Cerezo Téllez; Cristina Díaz Del Campo Gómez-Rico; Carlos Gutiérrez Ortega Journal: J Chiropr Med Date: 2016-11-23
Authors: María Nieves Muñoz-Alcaraz; Antonio José Jiménez-Vílchez; Mirian Santamaría-Peláez; Luis A Pérula-de Torres; María Victoria Olmo-Carmona; María Teresa Muñoz-García; Presentación Jorge-Gutiérrez; Jesús Serrano-Merino; Esperanza Romero-Rodríguez; Lorena Rodríguez-Elena; Raquel Refusta-Ainaga; María Pilar Lahoz-Sánchez; Belén Miró-Palacios; Mayra Medrano-Cid; Rosa Magallón-Botaya; Luis A Mínguez-Mínguez; Josefa González-Santos; Jerónimo J González-Bernal Journal: J Clin Med Date: 2022-04-16 Impact factor: 4.964
Authors: María Nieves Muñoz-Alcaraz; Luis Ángel Pérula-de-Torres; Jesús Serrano-Merino; Antonio José Jiménez-Vílchez; María Victoria Olmo-Carmona; María Teresa Muñoz-García; Cruz Bartolomé-Moreno; Bárbara Oliván-Blázquez; Rosa Magallón-Botaya Journal: BMC Cancer Date: 2020-11-09 Impact factor: 4.430